A decade of Clinical Trials

Steven N Goodman
My colleague and then Society for Clinical Trials (SCT) board member Kay Dickersin called me in spring of 2003 to ask a favor: would I consider taking on the editorship of the society journal, Controlled Clinical Trials? I protested vigorously; too much time, I said, not enough help, no support, I had papers to write, etc, etc. All true, but I knew I would say yes. Editing had long been in my blood, and to be able to continue the strong journal tradition established by Curt Meinert, the founding editor, Janet Wittes and then Jim Neaton was too tempting. Now, 10 years and over 660 published articles later, I am glad I did.
But had I known then what I was about to face, I might have demurred. Why? The society was in negotiation with the publisher Elsevier to renew the journal contract. A decision was soon to be madewith my concurrence -that we should jump ship. This meant that I was not about to take over Controlled Clinical Trials, but rather a new journal with a new name, no Medline listing, no impact factor, no institutional subscriptions, no articles in the queue, no staff, little money, and an empty Excel spreadsheet to manage articles that would somehow appear from somewhere.
What we did have was a dedicated editorial boardall of whom moved to the new journal -and a society membership that provided the initial subscriber base and source of articles. Looking at the contents of the first issue, one sees what that meant: a lively and eclectic collection of articles and commentaries that still inform and entertain, every one written by someone in the SCT or a colleague. There was a mix of methodology; one on dynamic treatment regimens by Lavori and Dawson [1] , three on data monitoring committees, two from the DAMO-CLES group (Data Monitoring Committees: Lessons, Ethics, Statistics) [2] [3] [4] , a delightful retrospective and accompanying editorial on the Salk polio vaccine trial [5, 6] , and a very nice article on the groundbreaking model of 'coverage under evidence development' embodied by the National Emphysema Treatment Trial [7] , followed by four terrific commentaries. But my favorite, 10 years later, was a profile of a founding SCT member, Paul Meier [8] , by my colleague and erstwhile associate editor Harry Marks [9] , neither of whom survived the ensuing decade. That interview, which I commend to all readers who missed it, was a tribute to both Paul and Harry's wide-ranging scholarship, knowledge, and humanity, and provided rich material for Paul's obituaries after his death in 2011.
That first issue was a harbinger of a decade spent exploring in the journal the multifaceted nature and the scholarship around the methods of human experimentation, which encompasses the fields of statistics, medicine, biology, ethics, epidemiology, economics, history, law, policy, sociology, study design, inference, philosophy, informatics, and yet other fields, with a soupcon of passion. It is hard not to enjoy playing in that sandbox.
But as I was warned by a sage colleague at the time, it is not the inaugural issue that tries editors' souls, but the second one. And so it was. This forced me to contemplate some existential questions, like 'What is the minimum number of articles that can legitimately be considered a journal ''issue?'''. The answer had a surprisingly concrete foundation; the number of pages whose thickness was sufficient to fit the words Clinical Trials on the spine of the bound journal. That turned out to be about five articles, the precise number comprising the second issue, and several thereafter. I confess this led to occasional musing about the joys of heavier gauge paper.
A medical editor colleague, puzzled when I told him I was taking on this job, asked what there was left to learn about clinical trials. The 600+ articles published since then in this journal represent just a first chapter of an answer. Amazingly, the need to develop further the theory and application of randomized clinical trials is now a pressing national priority. With health-care costs crushing the nation's economy without concomitant return, and a clinical trial model involving the creation of a parallel care system that is similarly unsustainable, policymakers are increasingly demanding that we learn about medical treatments and the provision of medical care in ways that are faster, cheaper, better and more relevant to a wider swath of providers and patients. This has led to a variety of initiatives and grassroots activities to transform clinical trials, such as Salim Yusuf's sensible clinical trials guidelines efforts [10] , the Food and Drug Administration (FDA)-supported clinical trials transformation initiative (www.trialstransformation.org), the National Institutes of Health (NIH) Collaboratory (www.nihcollaboratory.org), and the Patient Centered Outcomes Research Institute (www.pcori.org).
In the methods realm, this has meant increased appreciation of the potential value -economic, scientific, and ethical -of adaptive designs (particularly Bayesian) [11] , point-of-care randomization, causal inference methods [12, 13] , cluster randomization, use of information derived from electronic health records and new technologies, and methods to recruit and retain hard-to-reach populations [14, 15] . Issues around the meaningful engagement of patients and other consumers in the clinical trial enterprise also are being increasingly recognized as valuable to the science, conduct and ultimate utility of clinical trials [16, 17] .
There has been an increasing awareness of the importance of conducting and reporting research in an unbiased and reproducible fashion, as well as that of open sharing of protocols, code, and trial data. This last decade has seen the ascendancy of trial registration, for which the SCT produced its first position paper [18] . The next decade will see new policies, standards, methods, and incentives for data sharing.
Finally, the ethical tension at the heart of clinical trials will continue to play out in unpredictable and surprising ways, as reflected recently with the maelstrom around the Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) [19, 20] . This journal has been and will continue to be a forum where ethical issues are discussed in a sophisticated fashion [21, 22] .
Editing is a bit like scouting in sports; one of its pleasures is akin to discovering and developing a talented minor league prospect that other major league teams have missed. In our case that was Dean Fergusson's article on redundant and uncited trials of aprotinin [23] , whose value and originality some prominent journals did not appreciate. This was the first and only article published in the journal that garnered attention in the lay press [24] and remains one of the more highly cited. That this work was first presented in a SCT Student Scholarship session, with Dr Fergusson becoming a deputy editor of this journal in 2014 makes it part of a particularly gratifying cycle. On the other end of the development spectrum, the journal has had the good fortune to serve as a platform for that veteran's veteran of clinical trials, David Sackett, who is now up to the 19th chapter of his Clinician-trialist Rounds [25] , distilling and sharing a lifetime of lessons and good cheer to nurture the careers of young clinical trialists.
I had planned to use this last editorial to highlight some of my favorite articles published in the journal over the last decade, but there were just too many. (For readers who want to peruse our oeuvre to date, put the following string into PubMed search box, including the quotes: 'Clinical trials (London, England)'[Journal].) However, I will highlight one particularly fortuitous concordance of articles that the journal was lucky enough to be able to publish side by side. These were two chronicles of the early stopping of the Woman's Health Initiative (WHI), one told from the perspective of the coordinating center [26] , and the other from Janet Wittes and colleagues, from the data and safety monitoring board [27] . Telling the same story from these two different angles provided a textured view of the reality and drama of clinical trials that few other written treatments have matched. As I concluded in an editorial about the pairing, 'These will not be the last words we hear about the WHI, but for designers, coordinators and monitors of clinical trials, they may be among the most important' [28] .
Having exceeded the word limit allotted to this piece by the editor, it must come to a close. I do so with several thanks. The first goes to the SCT for allowing me the extraordinary privilege of leading its new/old journal for this last decade, and providing consistent moral and material support. The second is to my indefatigable and invaluable associate editors, many of whom have stuck with the journal not only through this entire 10 years, but many for years before that, most of whom will continue. Third is to my family, particularly my youngest children Eli and Sarah, whose formative years coincided with the journal's, and who have assembled a legal dossier of forfeited evenings and weekends. Fourth is to my two deputy editors, Barbara Hawkins and Dennis Dixon, who have functioned effectively as surrogate editors for an increasing volume of papers over the past 2 years. Fifth is to the journal's preternaturally gracious, capable, and wise managing editor, Dr. Roberta (Bobbi) Scherer, who has served as the face and voice of the journal for 7 years, protecting it (barely) from my worst habits, protecting me (effectively) from occasionally restive contributors, and sometimes stepping in as associate editor, reviewer, copy editor, and all-purpose problem solver. Perhaps I could have done it without her, but surely not as happily and not nearly as well.
My final and most heartfelt thanks goes to the journal reviewers and contributors over this last decade, particularly those who bet on its success during those early days when their later PubMed indexing could not be assured. Many prospective authors envision editors as all-powerful. In fact, it is the contributors who control the fate of a journal; they write it, not the editor. We just get to pick and choose, cajole and persuade, and try to host a party that others will want to attend.
Even though it is easy to say an editorial tenure of 10 years is enough, handing off a pre-teen nurtured through infancy and toddlerhood is hard. But it helps to know that this one is being delivered into the capable care of Colin Begg, a long-time SCT colleague and associate editor who will now take the helm. I wish him and his team good luck, and look forward to watching the continued flourishing of the journal under his editorship.
